Make a history that explains the result.
For each approach, record its name, approximate duration, treated areas, changes noticed, side effects and why it ended. “Did not work” may mean no colour return, continued spread, irritation, cost or an impossible routine.
These are different problems. If a routine was difficult to follow, describing the difficulty helps interpret its result. Missing records do not prevent a review; bring what you remember.
“My face seemed to improve, but the travel meant I stopped after three months” gives a different starting point from “Phototherapy failed.”
Was the trial enough to answer the question?
Ask what duration and attendance were needed to assess the particular approach. A brief attempt and a full supervised course do not establish the same thing.
Do not repeat a long course simply because someone says to try harder. Ask what would change: the target area, the combination, monitoring or whether you can maintain the routine.
- What outcome were we measuring?
- Was there a baseline photograph or score?
- Was benefit too small, or was the burden too large?
- What is the rationale for another attempt?
Match the next route to the problem now.
| Your situation | Options to discuss | Before deciding |
|---|---|---|
| New or enlarging areas | Reassess activity | Use the changing-patches journey. |
| Partial colour return | Review benefit by site | Agree the reason to continue, combine or change. |
| Stable localised resistant patches | Specialist procedural assessment | Review stability and procedure risks. |
| A plan predating newer options | Assess current eligibility | Read dated evidence and approval details. |
| A routine that no longer fits | Discuss simplifying or revising it | Explain the actual barrier before changing prescriptions. |
A newer medicine is not automatically a better fit. It should solve a defined problem with a commitment and risk profile you understand.
How do you judge a promising result?
Identify whether the claim concerns an approved indication, a peer-reviewed trial or an early announcement. Check the participants’ age, vitiligo type, affected areas and previous treatment.
F-VASI75 means a threshold of improvement in a facial scoring measure, not that every participant regained 75% of all body colour. The time point and comparison group matter. A six-month facial result is not a forecast for your hands.
Ask about adverse effects, monitoring and what happened after the initial trial period. The latest-developments page explains specific results and what they do not establish.
Compare the complete commitment.
Decide what is manageable in money, travel and time per month. Ask for consultation fees, supply costs, laboratory monitoring, device or session charges and follow-up costs.
If insurance or public coverage applies, ask about prior approval and the documents required. If paying directly, check the ongoing expense rather than only the first prescription. These are practical eligibility questions, not a test of commitment.
Phase 2 of OneVitiligo aims to address access through partnerships. This sample does not yet arrange medicines, devices, funding or treatment.
Leave with reasons, not just another prescription.
Ask for a plan that names the goal, option, trial period, review measure and the reason to continue or change. If a promise is vague, ask what specific outcome would make the plan worthwhile.
You can say: “I want care, but I need a routine I can sustain.” Emotional support does not need to wait until every skin treatment has been tried. Your goals can change even when your diagnosis has not.